LivaNova PLC
LIVN
Classement en actions
#3798
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Prix de l'action
$80.35
Capitalisation boursière
$4.41B
Changement (1 jour)
2.83%
Changement (1 an)
48.52%
Pays
GB
Échange LivaNova PLC (LIVN)
Catégorie
Healthcare
EPS pour LivaNova PLC (LIVN)
EPS au June 2026 TTM : $3.45
Selon les derniers rapports financiers et le cours de l'action de LivaNova PLC, l’EPS actuel de la société (TTM) est de $3.45. À la fin de 2023, la société avait un EPS de $0.33 une augmentation par rapport à celui de 2022, qui était de $-1.61.
Historique de l'EPS de LivaNova PLC de 2000 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $3.45 | 194.87% |
| 2024 | $1.17 | 254.55% |
| 2023 | $0.33 | -120.50% |
| 2022 | $-1.61 | -39.93% |
| 2021 | $-2.68 | -62.04% |
| 2020 | $-7.06 | 119.25% |
| 2019 | $-3.22 | -17.65% |
| 2018 | $-3.91 | 651.92% |
| 2017 | $-0.52 | -59.69% |
| 2016 | $-1.29 | -158.90% |
| 2015 | $2.19 | 8.42% |
| 2014 | $2.02 | 20.24% |
| 2013 | $1.68 | 29.23% |
| 2012 | $1.30 | -22.16% |
| 2011 | $1.67 | -40.99% |
| 2010 | $2.83 | 183.00% |
| 2009 | $1.00 | -356.41% |
| 2008 | $-0.39 | -80.60% |
| 2007 | $-2.01 | -15.19% |
| 2006 | $-2.37 | 364.71% |
| 2005 | $-0.51 | -275.86% |
| 2004 | $0.29 | 20.83% |
| 2003 | $0.24 | -119.83% |
| 2002 | $-1.21 | 611.76% |
| 2000 | $-0.17 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $3.11 | -9.86% |
US
|
|
| $3.59 | 4.06% |
IE
|
|
| $9.73 | 182.03% |
US
|
|
| $2.48 | -28.12% |
US
|
|
| - | - |
DE
|
